Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
NCT Number: NCT06256718
This study evaluates the implementation of evidence based strategies to optimize HPV vaccination in rural primary care settings. Some of the largest disparities in human papillomavirus vaccination (HPVV) rates exist in rural communities, which represent missed opportunities for cancer prevention. Primary care provider visits in these communities serve as a crucial opportunity to communicate the importance of timely vaccination that is essential to effective cancer prevention. This study implements and tests a practice-level intervention (PC TEACH) using practice facilitation of evidence-based strategies to expand reach to rural community-based primary care settings to optimize delivery and increase HPVV rates. PC TEACH program may help rural communities overcome access and awareness factors that keep them from receiving HPVV.
This study is active but is not currently recruiting participants.
Notify Me18 year and older
All sexes
Interventional
Not applicable
Buffalo, New York, 14263, United States
PRIMARY OBJECTIVES:
I. Identify practices from across 20 rural counties in central and western New York (CWNY) using registry data from New York State Immunization Information System.
II. Leverage established community network contacts of primary care practices across 20 rural counties in CWNY to support and enhance recruitment and retention activities.
III. Establish a Rural Cancer Health Equity Community Advisory Board (CAB) to enhance capacity to implement evidence-based cancer prevention activities in rural primary care settings (like primary care practice-level, medical office-based intervention [PC-TEACH] for Human Papilloma Virus Vaccine [HPVV]).
IV. Recruit rural primary care practices to implement PC TEACH intervention and contribute practice, provider, and patient-level data including adolescent vaccination rates.
V. Implement systematic practice-level changes (i.e., PC TEACH strategies) in rural community-based primary care practices.
V. Evaluate effectiveness of PC TEACH intervention and quality improvement within the practices using process and outcome evaluation measures.
OUTLINE:
Primary practice providers sites receive PC TEACH over 3.5 hours for 12 months.
After completion of study, primary care provider sites are followed up for 3-6 months.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Evidence-based strategy (PC TEACH)
Other names: Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational
Time frame: Up to 5 years (60 months)
To evaluate the impact (short and long-term) of the proposed PC TEACH (primary care practice-level, medical office-based intervention) intervention on human papilloma virus vaccine (HPVV) uptake and completion rates using a staggered (stepped-wedge) intervention schedule. Briefly, practice-specific vaccine rates data will be modeled as a function of time in intervention (0, 6, 12, 18, or 24 months), while adjusting for baseline rates collected prior to intervention for each practice. For vaccine rates, an additional factor for calendar time will be included in the model to address potential seasonal effects.
Time frame: Up to 5 years (60 months)
will evaluate the impact of the proposed PC TEACH intervention on age at using a staggered (stepped-wedge) intervention schedule. Briefly, practice-specific vaccine rates data will be modeled as a function of time in intervention (0, 6, 12, 18, or 24 months), while adjusting for baseline rates collected prior to intervention for each practice.
Roswell Park Cancer Institute
Other
Implementation of Evidence-Based Strategies to Optimize HPV Vaccination in Rural Primary Care Settings
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05057312
Communicable Diseases, DNA Virus Infections
Houston, Texas, United States
View Trial DetailsNCT06611540
Cervical Carcinoma, Communicable Diseases
Atlanta, Georgia, United States
View Trial DetailsNCT02816879
Anal Carcinoma, Anus Diseases
Los Angeles, California, United States
View Trial DetailsNCT06611553
Cervical Carcinoma, Communicable Diseases
Birmingham, Alabama, United States
View Trial Details